NCT05028803Completed
The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino Acids
The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino Acid Concentrations in Obese and Prediabetics.
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
The aim of this study is to reduce fasting circulating BCAA concentrations in volunteers using Sodium Phenylbutyrate. In addition, we aim investigate the effect of BCAA lowering on fasting blood glucose levels, insulin sensitivity measures and muscle metabolism.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 8 (actual)
- First submitted
- 25 Aug 2021
- Start date
- 1 Sept 2021
- Primary completion date
- 1 Sept 2023
- Lead sponsor
- University of Nottingham
- Diseases
- Obesity
- NCT number
- NCT05028803
What you commit to
- Study type: Interventional
- Participants enrolled: 8
- From 1 Sept 2021 to the primary completion date, 1 Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- • Specify any diseases/disorders/ conditions that would preclude entry into the study
- Females
- History or current psychiatric illness
- History or current neurological condition (e.g. epilepsy)
- Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance (this must remain for ALL UoN FMHS UREC approved studies)
- A BMI \< 30kg·m2
- FBG \>7mmol/L/ or HbA1c \>48mmol/mol
- Metabolic disease; Active inflammatory bowel disease
- Chronic kidney disease
- Malignancy
- Recent (6 mo) steroid/ hormone therapy
- Clotting dysfunction
- Musculoskeletal/ neurological disorders
- Active cardiovascular disease or recent cardiac event
- Respiratory disease (not including well-controlled asthma)
Who the study is looking for
- • Participant is willing and able to give informed consent for participation in the study
- Not currently taking any medications
- Males between the ages of 18 - 60
- BMI ≥ 30 kg·m2
- FBG ≥ 6 mmol/L ≤ 7mmol/L or HbA1c ≥ 42 mmol/mol 48 ≤ mmol/mol
Age in the registry: 18 years to 60 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Nottingham Coordinator of this site? Confirm its status | Derby | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.